Sicherheit und Verträglichkeit von Yaq-001 bei Patienten mit Zirrhose

Device: 4g Yaq-001;Other: 4g Placebo;Device: 8g Yaq-001;Other: 8g Placebo

Inclusion Criteria:

1. Male and female patients

2. Age = 18 years at screening

3. Clinical diagnosis of cirrhosis for any cause. Liver biopsy is not required

4. Cirrhotic patients with diuretic-responsive ascites and Child-Pugh score = 7-11
inclusive

5. Abstinence from alcohol for at least 4 weeks prior to screening

Exclusion Criteria:

1. Refusal or inability (lack of capacity) to give informed consent

2. Prohibited medication within 4 weeks before the start of the study treatment: all oral
antibiotics, immunosuppressants, long acting benzodiazepines or barbiturates and
antiviral medication

3. Change in dose of proton pump inhibitor therapy within 4 weeks before the start of the
study treatment

4. Patients with once daily medications in which orocaecal transit time is greater than
10 hours

5. Patients requiring medication in which the dosing schedule is three times per day or
greater

6. Antiviral therapy for hepatitis C within 3 months prior to screening

7. Hospital admission for liver-related indication for at least 4 weeks (except
paracentesis)

8. BMI > 35 or BMI < 18

9. Clostridium Difficile diarrhoea within 4 weeks before the start of the study treatment

10. Uncontrolled infection (chronic viral hepatitis is not an exclusion criterion)

11. Human immunodeficiency virus

12. Presence of a transjugular intrahepatic portosystemic shunt (TIPSS)

13. Participation in any clinical study of an investigational medicinal product within 30
days of five half-lives of the investigational product, whichever is longer

14. Presence of clinically relevant cardiovascular, pulmonary, gastro-intestinal, renal,
hepatic, metabolic, haematological, neurological, psychiatric, systemic, ocular,
gynaecologic or any acute infection disease or signs of acute illness that, in the
opinion of the investigator, might compromise the patient's safe participation in the
trial and/or results in a WHO performance status of 2 or more.

15. Presence of the history of cancer within the past 5 years with exception of
hepatocellular carcinoma within Milan criteria, adequately treated localised basal
cell carcinoma of the skin, in situ cervical carcinoma or solid malignancy surgical
excised in total without recurrence for five years.

16. Women of child bearing potential. Only postmenopausal women or with surgical
sterilization will be included.